Latest / Decera Clinical Education Oncology Podcast
Available and Emerging Therapies for Progressive/Recurrent ROS1-Altered Advanced NSCLC
In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available and emerging clinical data for second-line and beyond treatments in patients with recurrent ROS1-altered advanced NSCLC including:
Assessing ROS1-TKI resistance mutations with tumor and liquid biopsies in patients with ROS1-altered advanced NSCLC
Previous TKI-treated cohort from the TRIDENT-1 study: efficacy of repotrectinib in patients with recurrent ROS1-altered NSCLC and measurable baseline brain metastases
Phase II TRUST-1 trial of taletrectinib: activity in patients with known…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.